Search Results

Business

ExcellGene SA and Cytovance Biologics Join Forces to Transform Large Molecule Biologics Development and Manufacture

ExcellGene SA proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization based in the USA.

May 8, 2024

·

3 min read

Business

Cytovation Announces Appointment of Ellen Lubman, MBA to its Board of Directors

Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, announced the election of Ellen Lubman, MBA, to its Board of Directors.

December 20, 2023

·

3 min read

Press Releases

Cytovation to present full safety and efficacy data from the CICILIA Phase I/IIa trial evaluating CY-101 in solid tumors at ESMO 2024

September 13, 2024

·

3 min read

Cytovance Biologics and Alcami Unite to Deliver End-to-End Solutions for Biologics Developers

Cytovance Biologics has announced a strategic collaboration with fellow CDMO Alcami Corporation to expand its large molecule biologic manufacturing and sterile fill finish offering.

December 11, 2023

·

3 min read

Business

Cytovation appoints Olav Hellebø to its Board of Directors

Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the appointment of Olav Hellebø to its Board of Directors.

July 5, 2023

·

2 min read

Cytovance Biologics Announces Dr. Axel Schleyer to Expand Footprint and Service Offering as Chief Commercial Officer

Cytovance Biologics, a leading full-service mammalian and microbial large molecule contract development and manufacturing organization (CDMO), announced today the addition of Axel Schleyer, Ph.D., MBA,

September 26, 2023

·

2 min read

Large Molecule CDMO, Cytovance Biologics, and Custom Strain Development Expert, Vectron Biosolutions, Partner to Improve Development of Complex Microbial Molecules

Cytovance Biologics announced a strategic, international collaboration with Vectron Biosolutions to add customized E. coli strain development to the CDMO’s microbial program.

October 10, 2023

·

5 min read

Drug Development

Cytovation Reports Promising Interim Results from Phase 1/2a CICILIA Study with CyPep-1 in Solid Tumors

Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class, dual-acting targeted tumor immunotherapy, announces positive initial data from Part 2 of its Phase 1/2a CICILIA basket trial with all trial endpoints met.

October 11, 2023

·

3 min read

Business

Cytovance Biologics Announces Ping Zhang as Chief Executive Officer

Cytovance® Biologics announces the appointment of Mr. Ping Zhang as Chief Executive Officer.

January 16, 2023

·

2 min read

Business

Cytovation appoints Iman Barilero as Chief Development Officer

Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that Dr. Iman Barilero has joined the company as Chief Development Officer.

March 21, 2023

·

2 min read